News & Updates

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.

Use of neoadjuvant daromun in addition to surgery is safe and provides survival benefits in patients with resectable, locally advanced melanoma, results of the PIVOTAL study have shown.

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

An exosome-based liquid biopsy showed favourable signals for noninvasive, early detection of pancreatic ductal adenocarcinoma (PDAC) in a prospective study.

An investigational blood-based test performs satisfactorily for the early detection of colorectal cancer (CRC), having met all prespecified primary endpoints in the large PREEMPT CRC trial.

Patients with metastatic prostate cancer can safely engage in intense exercise training to improve survival outcomes, suggests a study presented at AACR 2024.

In young breast cancer survivors harbouring BRCA1/2 pathogenic variants, using assisted reproductive techniques (ART) to conceive did not appear to negatively affect maternal or pregnancy outcomes, findings from an international retrospective cohort study suggest.

The intermittent 48-h “gap” schedule of olaparib in combination with carboplatin/paclitaxel and anthracycline chemotherapy provides substantial survival benefits in patients with germline BRCA-mutated breast cancer (gBRCA) regardless of their pathological complete response (pCR) status, results of the PARTNER trial have shown.

Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.